FDA Clears Lupin API Site Of NDMA Risk, Compliance Efforts Ongoing

Lupin’s Tarapur API site for ‘sartans’, including valsartan, has been cleared of NDMA concerns by the US FDA, and the Indian firm has also provided analytical reports to EU authorities to affirm its case. The FDA inspection, though, did end with a lone observation at the site.